Illustration showing long COVID patients revitalized by fluvoxamine treatment in a clinical trial, with scientists and physician highlighting study results.
AI에 의해 생성된 이미지

Fluvoxamine eases severe fatigue in long COVID patients

AI에 의해 생성된 이미지
한국어

A study shows the antidepressant fluvoxamine reduces severe fatigue in long COVID patients. In a randomized trial of 399 adults, it was compared with metformin and placebo. Physician Judith Bruchfeld describes the findings as interesting.

A new study, reported by Dagens Medicin, examined treatments for severe fatigue in adults with long COVID – fatigue that does not improve with rest. 399 patients were randomized to receive fluvoxamine, the type 2 diabetes drug metformin, or placebo.

Fluvoxamine, used for depression, effectively reduced fatigue. Metformin and placebo showed no comparable effect in the study.

"These are interesting data from a well-conducted study. Fluvoxamine is a well-known drug with relatively few side effects and something that can be tested clinically on selected patients," says Judith Bruchfeld, senior physician in infectious medicine at Karolinska University Hospital who researches long COVID, to the newspaper.

The drug is sold in Sweden as Fevarin but is not subsidized.

사람들이 말하는 것

Reactions on X to the fluvoxamine long COVID fatigue study are cautiously optimistic, with medical professionals and patients noting its RCT design and significant fatigue reduction versus placebo. Skeptics highlight the modest clinical effect size and lack of mechanistic data. Metformin showed no benefit, and some raised concerns about SSRI side effects.

관련 기사

Realistic illustration of long COVID patients improving from fatigue and brain fog via NAD+ supplement trial at Massachusetts General Hospital.
AI에 의해 생성된 이미지

NAD+ supplement shows early promise for long COVID fatigue and brain fog

AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨

A randomized controlled trial at Massachusetts General Hospital tested high-dose nicotinamide riboside, a vitamin B3 derivative, to boost NAD+ levels in people with long COVID. Although between-group differences were limited, participants who took the supplement for at least 10 weeks reported improvements in fatigue, sleep, mood, and some executive function measures compared with their own baseline, suggesting potential benefits for some individuals despite mixed overall results.

Long COVID research points to lingering virus, inflammation and micro-clots—while treatments remain unproven

New research syntheses suggest long COVID—typically defined as symptoms lasting at least two months after SARS‑CoV‑2 infection with no alternative explanation—may be driven by overlapping processes including viral persistence, chronic inflammation and tiny blood clots. Scientists say there are still no approved, evidence-based treatments, though rehabilitation strategies and several experimental approaches, including metformin given early in infection, are under study.

International study finds U.S. long COVID patients report more brain fog and psychological symptoms than peers in India and Nigeria

AI에 의해 보고됨 사실 확인됨

A Northwestern Medicine-led study of more than 3,100 adults with long COVID found that non-hospitalized participants in the United States reported substantially higher rates of brain fog, depression/anxiety and insomnia than participants in Colombia, Nigeria and India—differences the researchers say likely reflect cultural factors and access to care as much as biology.

유럽

Pre-pandemic ill health common among those with postcovid

건강

Study links major depression in young adults to altered cellular energy patterns in brain and blood

건강

RECOVER trial suggests vagus nerve stimulation benefits some patients with severe treatment-resistant depression for at least two years

Study links 259 genes to chronic fatigue syndrome risk

Researchers have identified 259 genes associated with chronic fatigue syndrome, or myalgic encephalomyelitis, in the largest genetic analysis to date. This finding multiplies the number of implicated genes by six compared to a study just four months earlier. The work suggests potential paths for new treatments by targeting genetic factors.

Genetic modifier offers new route toward Friedreich’s ataxia therapy

AI에 의해 보고됨 사실 확인됨

Scientists have identified a genetic modifier that helps cells cope with the loss of frataxin, the protein at the core of Friedreich’s ataxia. By lowering activity of the FDX2 gene, experiments in worms, human cells, and mice showed that key energy‑producing processes can be restored, pointing to a potential new treatment strategy.

Exercise matches antidepressants for depression relief, review shows

A new Cochrane Library review of dozens of trials confirms that regular exercise can alleviate depression symptoms as effectively as antidepressants or cognitive behavioral therapy. Even light activities like walking may provide significant benefits. Researchers analyzed nearly 5,000 adults with depression, finding moderate reductions in symptoms across various exercise types.

알츠하이머 약물 시험, 암의 다중 표적 접근법 채택

AI에 의해 보고됨

알츠하이머 시험이 암 연구에서 영감을 받은 다중 표적 접근으로 전환 중이며, Novo Nordisk의 세마글루타이드 실패에도 불구하고. Eli Lilly의 Kisunla와 Eisai 및 Biogen의 Leqembi 두 약물만이 진행을 늦추기 위해 널리 승인됨. 이러한 진화는 뇌 퇴화 질환을 복잡한 시스템으로 간주하며, 전 세계적 영향 속에서 이를 멈추는 새로운 방법을 모색함.

2026년 03월 26일 05시 56분

Study links a distinct CD14+ monocyte state to fatigue and breathing symptoms in long COVID

2026년 03월 15일 22시 52분

Large VIVID trial finds high-dose vitamin D3 did not lessen acute COVID-19 severity, but adherence analysis suggests possible long COVID signal

2026년 03월 13일 23시 47분

Severe COVID or flu may raise lung cancer risk years later

2026년 02월 16일 23시 59분

Single dose of DMT eases depression symptoms in small trial

2026년 01월 08일 16시 54분

Exercise can ease depression symptoms about as much as therapy, Cochrane review finds

2026년 01월 06일 14시 15분

Study finds Tamiflu reduces neuropsychiatric risks in children with flu

2026년 01월 01일 08시 26분

US FDA approves first oral pill for thalassaemia anaemia

2025년 12월 17일 14시 56분

Promising medical advances for 2026

2025년 12월 15일 15시 17분

Researchers explore role of co-infections in long COVID symptoms

2025년 11월 18일 13시 41분

Metformin may blunt some exercise benefits, Rutgers-led trial suggests

 

 

 

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부